Literature DB >> 33687881

The Situation of Small Molecules Targeting Key Proteins in combatting SARS-CoV-2: Synthesis, Metabolic Pathway, Mechanism of Action, and Potential Therapeutic Applications.

Farzaneh Sorouri1, Zahra Emamgholipour2, Maryam Keykhaee1, Alireza Najafi3, Loghman Firoozpour2, Omid Sabzevari4, Mohammad Sharifzadeh4, Alireza Foroumadi2, Mehdi Khoobi1.   

Abstract

Due to the high mortality rate of the 2019 coronavirus disease (COVID-19) pandemic, there is an immediate need to discover drugs that can help before a vaccine becomes available. Given that the process of producing new drugs is so long, the strategy of repurposing existing drugs is one of the promising options for the urgent treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease. Although FDA has approved Remdesivir for the use in hospitalized adults and pediatric patients suffering from COVID-19, no fully effective and reliable drug has been yet identified worldwide to treat COVID-19 specifically. Thus, scientists are still trying to find antivirals specific to COVID-19. This work reviews the chemical structure, metabolic pathway, and mechanism of action of the existing drugs with potential therapeutic applications for COVID-19. Furthermore, we summarized the molecular docking stimulation of the medications related to key protein targets. These already established drugs could be further developed, and after their testing through clinical trials, they could be used as suitable therapeutic options for patients suffering from COVID-19. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  3CLpro inhibitors; COVID-19; RdRp inhibitors; mechanism of action; metabolic pathway; viral entry inhibitors

Mesh:

Substances:

Year:  2022        PMID: 33687881     DOI: 10.2174/1389557521666210308144302

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  1 in total

Review 1.  A Review of Virus-Like Particle-Based SARS-CoV-2 Vaccines in Clinical Trial Phases.

Authors:  Mohammad Sharifzadeh; Negar Mottaghi-Dastjerdi; Mohammad Soltany Rezae Raad
Journal:  Iran J Pharm Res       Date:  2022-05-09       Impact factor: 1.962

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.